BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE | N020186 | TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Lachman Consultant Services Inc. FDA-2014-P-0984 · 2 docket documents Lachman Consultant Services Inc. filed this petition under Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA declare Bisoprolol Fumarate and Hydrochlorothiazide Tablets at strengths of 5 mg/12.5 mg and 10 mg/12.5 mg suitable for submission as an ANDA, citing th | Other | 2014-07-16 | Open | Lachman Consultant Services Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.2072
per ea
Lowest NADAC/Unit
$0.1862
per ea
Brand NDCs
0
Generic NDCs
3
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00093324356BISOPROLOL-HYDROCHLOROTHIAZIDE 10-6.25 MG TAB | $0.2072 | EA | Generic | — | 2026-06-17 |
| 00093324201BISOPROLOL-HYDROCHLOROTHIAZIDE 5-6.25 MG TAB | $0.2045 | EA | Generic | — | 2026-06-17 |
| 00093324101BISOPROLOL-HYDROCHLOROTHIAZIDE 2.5-6.25 MG TB | $0.1862 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.